ReviewFrontiers in medicine2025
Meibomian gland dysfunction in Sjögren's disease.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Beyond anti-SSA and anti-SSB. The clinical significance of new antibodies in the diagnosis of Sjögren disease.Rheumatology international · 2026Pooled it
- Autoimmune Diseases of the Eyelid Skin: Molecular Pathways, Clinical Manifestations, and Therapeutic Insights.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
For many years, lacrimal gland dysfunction was considered the primary cause of dry eye disease in Sjögren's Disease (SjD). However, recent studies reveal that meibomian gland dysfunction (MGD) is also a significant contributor in dry eye associated with SjD. Recent evidence shows severe meibomian gland damage, reduced tear lipid layer thickness, and abnormal tear evaporation rates, which could exacerbate dry eye symptoms in SjD. These findings challenge the traditional view of SjD dry eye as solely aqueous-deficiency and highlight the role of evaporative dry eye in SjD. While the exact mechanisms linking MGD to SjD remain unclear, researchers propose that inflammation, androgen deficiency, and neurological factors may play key roles. Despite these findings, there is limited research on targeted therapies for SjD-related MGD, which may contribute to why many SjD patients do not experience optimum relief with conventional treatments. This report examines the manifestation of MGD in SjD, explores potential pathophysiological mechanisms, and reviews current management strategies aimed at addressing SjD-related MGD, highlighting the need for further research to improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.